Cardlytics Inc (NASDAQ:CDLX) Director Sells 75,284 Shares

Cardlytics Inc (NASDAQ:CDLX) Director Bryce Youngren sold 75,284 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $24.10, for a total value of $1,814,344.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Bryce Youngren also recently made the following trade(s):

  • On Tuesday, May 28th, Bryce Youngren sold 100,000 shares of Cardlytics stock. The shares were sold at an average price of $23.04, for a total value of $2,304,000.00.

Shares of NASDAQ:CDLX opened at $25.98 on Friday. The firm’s 50 day simple moving average is $23.17. Cardlytics Inc has a twelve month low of $9.80 and a twelve month high of $28.29. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.99.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Thursday, May 9th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.31. Cardlytics had a negative return on equity of 84.02% and a negative net margin of 25.53%. The firm had revenue of $35.99 million during the quarter, compared to the consensus estimate of $36.11 million. During the same quarter in the prior year, the company earned ($0.35) EPS. The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. On average, equities research analysts forecast that Cardlytics Inc will post -1.21 earnings per share for the current fiscal year.

CDLX has been the topic of a number of recent research reports. Zacks Investment Research downgraded Cardlytics from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. SunTrust Banks restated a “buy” rating and issued a $25.00 target price on shares of Cardlytics in a research note on Tuesday, May 21st. KeyCorp boosted their target price on Cardlytics from $25.00 to $26.00 and gave the company an “overweight” rating in a research note on Friday, May 10th. Finally, ValuEngine downgraded Cardlytics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $22.71.

A number of large investors have recently made changes to their positions in CDLX. New York State Common Retirement Fund raised its holdings in Cardlytics by 80.0% in the 4th quarter. New York State Common Retirement Fund now owns 9,000 shares of the company’s stock valued at $97,000 after acquiring an additional 4,000 shares in the last quarter. First Mercantile Trust Co. raised its holdings in Cardlytics by 115.0% in the 4th quarter. First Mercantile Trust Co. now owns 12,893 shares of the company’s stock valued at $140,000 after acquiring an additional 6,897 shares in the last quarter. TIAA CREF Investment Management LLC acquired a new position in Cardlytics in the 3rd quarter valued at approximately $202,000. Gamco Investors INC. ET AL acquired a new position in Cardlytics in the 1st quarter valued at approximately $256,000. Finally, Teachers Advisors LLC acquired a new position in Cardlytics in the 3rd quarter valued at approximately $263,000. Hedge funds and other institutional investors own 73.51% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Back-End Load

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.